Coronary Artery Calcium Score Predicts Long-Term Cardiovascular Outcomes in Asymptomatic Patients with Type 2 Diabetes

Meng-Huan Lei¹, Yu-Lin Wu², Sheng-Liang Chung¹, Chao-Chin Chen¹, Wei-Cheng Chen¹ and Yu-Chen Hsu¹

¹Division of Cardiology, Department of Internal Medicine, Lo-Tung Poh-Ai Hospital, Luodong Township, Taiwan
²Department of Nursing, St. Mary’s Junior College of Medicine, Nursing and Management, Luodong Township, Taiwan

Aims: Type 2 diabetes mellitus (T2DM) is no longer regarded as a coronary risk equivalent, and heterogeneity of cardiovascular risk exists, suggesting that further risk stratification should be mandatory. This study aimed to determine the prevalence and clinical predictors of coronary artery calcium (CAC) score, and evaluate the CAC score as a predictor of cardiovascular outcome in a large asymptomatic T2DM cohort.

Methods: A total of 2,162 T2DM patients were recruited from a Diabetes Shared Care Network and the CAC score was measured. Cardiovascular outcomes were obtained for 1,928 patients after a follow-up of 8.4 years. Multiple regression analysis and Cox proportional hazard regression were applied to identify clinical predictors of CAC and calculate the incidence and hazard ratios (HRs) for all-cause mortality and cardiovascular events by CAC category.

Results: Of the recruited patients, 96.8% had one or more risk factors. The distribution of CAC scores was as follows: CAC=0 in 24.2% of the patients, 0 < CAC ≤ 100 in 41.5%, 100 < CAC ≤ 400 in 20.3%, CAC > 400 in 14.7%. The multivariable predictor of increased CAC included age (years) (odds ratio, 1.07; 95% confidence interval, 1.06–1.08), male sex (1.82; 1.54–2.17), duration (years) of T2DM (1.07; 1.05–1.09), and multiple risk factors (1.94; 1.28–2.95). Increasing severity of CAC was associated with higher all-cause or cardiac mortality and higher incident cardiovascular events. The HRs for cardiac death or major cardiac events in CAC > 400 vs CAC=0 were 8.67 and 10.52, respectively (p<0.001)

Conclusion: CAC scoring provides better prognostication of cardiovascular outcome than traditional risk factors in asymptomatic T2DM patients, and may allow identifying a high-risk subset for enhancing primary prevention.

Key words: Coronary artery calcium score, Primary prevention, Cardiovascular outcome, Type 2 diabetes mellitus

Introduction

Cardiovascular disease is the leading cause of death in 65%–75% of diabetic patients¹. Generally, diabetic patients have more extensive atherosclerosis with a higher prevalence of multi-vessel coronary artery disease (CAD), frequent silent myocardial ischemia, and infarction with a poorer prognosis. Diabetes is associated with at least a two-fold increased risk of coronary heart disease (CHD) and a two- to four-fold increased risk of CHD- and stroke-associated mortality compared those in patients without diabetes²-⁵. From a pooled analysis of more than one million Asian participants, patients with diabetes had a 1.89-fold risk of all-cause death and a two-fold risk of cardiovascular-related death compared with patients without diabetes⁶.

Two decades ago, diabetes was regarded as a “CHD risk equivalent,” implying a 10-year cardiovascular risk of > 20% for every diabetic patient according to Haffner’s report⁵ and other large observational studies⁶, ⁷. However, several studies of different population cohorts provided varying conclusions on the concept of coronary risk.
Coronary Artery Calcium, Cardiovascular Risk Stratification

In a systematic review and meta-analysis of 13 studies enrolling 45,108 patients with a mean follow-up of 13.4 years, Bulugahapitiya et al. showed that patients with diabetes without prior myocardial infarction have a 43% lower risk of developing total CHD events compared with patients without diabetes with previous myocardial infarction, not supporting the hypothesis of diabetes being a “CHD risk equivalent”. New guidelines have acknowledged the heterogeneity of cardiovascular risk in diabetic patients and suggested further risk stratification before universal treatment.

Coronary artery calcium (CAC) score measured by multi-detector computerized tomography is a reliable measure of subclinical atherosclerosis. The presence, extent, and progression of CAC have been shown to enable better prognostication of adverse cardiovascular events than traditional risk factors and global risk scoring among asymptomatic intermediate-risk individuals. There is significant heterogeneity between traditional risk and observed events, with discrepant event rates driven by the directly observed burden of atherosclerosis. CAC scoring may help reclassifying individuals at intermediate-risk to low- or high-risk groups to aid clinical decision-making in primary prevention.

Patients with type 2 diabetes (T2DM) harbor larger amounts of CAC than nondiabetic patients of similar age. Some studies have demonstrated that increased CAC in individuals with T2DM is associated with increased prevalence of myocardial ischemia and more coronary events, and higher all-cause mortality. Zero CAC was present in one-third of T2DM patients and predicted low short-term risk of death (around 1% at 5 years). The aim of this study was to determine the prevalence and clinical predictors of CAC score in uncomplicated T2DM patients, and evaluate CAC score as a predictor of long-term cardiovascular outcome in a large asymptomatic Taiwanese T2DM cohort.

**Methods**

**Study Participants**

We recruited 2412 consecutive asymptomatic T2DM patients from Lan-Yan Diabetes Shared Care Network from August 2006 to August 2007 (61.2% referred by the Public Health Bureau of Yilan County, 31.3% from the Lo-Tung Poh-Ai Hospital, and 7.5% from local practitioners). Inclusion criteria were having T2DM for more than 1 year and age between 40 and 80 years old. The exclusion criteria were documented coronary artery disease, typical angina, abnormal resting electrocardiogram (e.g., Q waves and LBBB), cerebrovascular or peripheral arterial disease, or serious life-threatening illness. Seventy-six patients were excluded. One hundred and sixty-eight patients were not interested in taking part in the study and refused baseline blood test. Finally, 2162 subjects (aged 40 to 80 years, mean 64.5 ± 9.3, 48% male) fulfilled the eligibility criteria, provided informed consent in written form for collection of baseline and follow-up data, and underwent CAC score measurement.

**Risk Factor Assessment**

Information of participant demographic characteristics, medical histories, including traditional cardiovascular risk factors (hypercholesterolemia, hypertension, smoking, family history of premature CHD, macro/microalbuminuria), duration of T2DM, treatment history, height, weight, body mass index, waist-to-hip ratio, and blood pressure were recorded. Hypercholesterolemia was defined as total cholesterol >200 mg/dL, low-density lipoprotein cholesterol >100 mg/dL, high-density lipoprotein cholesterol <35 mg/dL, or being on statin treatment. Hypertension was defined as blood pressure >140/90 mmHg or being on anti-hypertensive treatment. Family history of premature CHD was determined by asking patients whether any member of their immediate family (parents or siblings) had a history of fatal or nonfatal myocardial infarction and coronary revascularization. Patients were considered to have a history of premature CHD if such events occurred before 55 years of age in male relatives or before 65 years of age in female relatives. Fasting blood and urine samples were obtained for checking glucose, HbA1c, lipid profiles, urea, creatinine, and urine microalbumin.

**CAC Scores Measurement**

CAC imaging was performed using a 16-sliced or 64-sliced multi-detector computerized tomography scanner (Siemens Somaton 16, Philips Brilliance 64) equipped with high-resolution detectors. Contiguous 3-mm slices were obtained during a single breath-hold starting at the carina and proceeding to the level of the diaphragm. Scan time was 100-ms per slice, with image acquisition electrocardiographically synchronized to 60% of the R-R interval. A calcified lesion was defined as ≥ 3 contiguous pixels, with a peak attenuation of at least 130 Hounsfield units. Each lesion was then scored using the method developed by Agatston et al. A single experienced radiologist blinded to the clinical data calculated all CAC scores. CAC scores were classified into four categories based on cut-offs that have been widely used in the literature as follows: 0, 0 < CAC ≤ 100
(mild CAC), 100 < CAC ≤ 400 (moderate CAC), and CAC > 400 (severe CAC).

**Clinical Endpoints Ascertainment**

Clinical endpoints include all-cause mortality, cardiac mortality, acute myocardial infarction (AMI), any coronary revascularization (percutaneous coronary intervention [PCI] and coronary artery bypass graft [CABG]), and ischemic stroke. Major CHD events were defined as combinations of cardiovascular mortality, AMI, and any coronary revascularization. All cardiovascular events were surveyed by a study nurse via telephone interview with the patient or a family member between 2014 and 2015 within a 14-month interval. Adequate information was obtained for 1928 patients.

**Statistical Analysis**

Data analysis was performed using the statistical SAS software 9.2 version. One-way ANOVA and chi-square test were applied to test for difference in demographic and risk factors and to describe the percentage of risk factors among four CAC categories. Multiple regression analysis was used to determine the relationships between cardiovascular risk factors and the severity of CAC. The incidence rate of clinical endpoints (all-cause mortality, cardiac mortality, non-cardiac mortality, major CHD, AMI, PCI, CABG, coronary revascularization, and ischemic stroke) among the four CAC categories was calculated and the chi-square test was used to determine the differences among four CAC categories. We constructed Kaplan–Meier cumulative-event curves for all-cause mortality, cardiac mortality, coronary revascularization, and major CHD events. Cox proportional-hazards regression was employed to estimate hazard ratios as compared between CAC categories for all endpoints, and all models were adjusted for age, diabetes duration, and number of risk factors. A two-sided \( p < .05 \) was considered to indicate statistical significance.

**Results**

**Baseline Characteristics**

Of 2,162 enrolled participants, 1,928 had complete demographic, risk factor, blood test, and endpoint data with a mean 8.4 years interval after CAC measurement, constituting the final analyzed population. The risk factors among the 1928 study participants were hypertension in 69.1% (96.2% being treated), hypercholesterolemia in 75.9% (26.9% on statin), smoking in 30.8%, family history of premature CHD in 7.3%, and macro/microalbuminuria in 41.6%. The distribution of coronary risk factors was 3.2% without any risk factor, 17.2% with one, 38.8% with two, and 40.8% with three or more risk factors. The mean T2DM duration was 7.0 ± 6.0 years, HbA1C was 8.0% ± 1.6%, and the mean body mass index was 26.8 ± 4.8 kg/m². The distribution of CAC scores was as follows: CAC=0 in 24.2% of the participants, 0 < CAC ≤ 100 (mild CAC) in 41.5%, 100 < CAC ≤ 400 (moderate CAC) in 20.3%, and CAC > 400 (severe CAC) in 14.7%. The medical treatments of the participants included aspirin use in 36.6%, statin in 26.8%, angiotensin-converting enzyme inhibitor in 14.7%, angiotensin receptor blocker in 19.5%, beta-blocker in 21.1%, oral hypoglycemic agents in 84.5%, insulin in 1.9%, and both anti-diabetic medication in 3.8%.

**CAC Score and Risk Factor Burden**

The baseline characteristics and risk factors condition among the four CAC category groups are shown in Table 1. Patients with higher CAC score tended to be older, of the male sex, had longer duration of T2DM, higher systolic blood pressure, poorer renal function, and lower high-density lipoprotein cholesterol. By multivariable analysis, only age (years) (odds ratio [OR], 1.07; 95% confidence interval [CI], 1.06–1.08), male sex (OR, 1.82; 95% CI, 1.54–2.17), and diabetic duration (years) (OR, 1.07; 95% CI, 1.05–1.09) were significant predictors of increased CAC (\( p < 0.001 \)). Any single traditional factor did not correlate with the severity of CAC. There was no difference in the severity of CAC in diabetic patients with two or less risk factors (Fig. 1). Only clustering of three or more risk factors predict increased CAC (OR, 1.94 vs 0 risk factor; 95% CI, 1.28–2.95; \( p = 0.002 \)). Among patients without any risk factor, 33.9% had a CAC score=0 and 11.3% had a CAC score >400, whereas among patients with 3 or more risk factors, 20.5% had a CAC score=0 and 16.4% had a CAC score >400.

**CAC Score and Cardiovascular Events**

During a mean 8.4 years follow-up, a total 211 all-cause and 43 cardiac death events and 207 major CHD events occurred. The incidence rate of all clinical endpoints is shown according to CAC score categories at Table 2. A stepwise increase in the observed event rate of all-cause mortality, major CHD (cardiac mortality, AMI, coronary revascularization), and ischemic stroke was seen with increasing severity of CAC score categories. The all-cause mortality and major CHD event rate were 6.4 and 3.9 per 1000 person-year, respectively, in diabetic patients with
Table 1. Baseline Characteristics among Four Coronary Artery Calcium (CAC) Categories (N=1,928)

| Variable                              | CAC=0 (N=466) | 0 < CAC≤100 (N=800) | 100 < CAC≤400 (N=392) | CAC > 400 (N=270) | P value |
|---------------------------------------|----------------|---------------------|------------------------|--------------------|---------|
|                                       | mean/N (SD)/%  | mean/N (SD)/%       | mean/N (SD)/%          | mean/N (SD)/%       |         |
| CAC value, AU                         | 0.0 (0.0)      | 28.1 (28.2)         | 218.5 (85.0)           | 1097.4 (762.6)      | < .001  |
| Age, years                            | 59.8 (9.4)     | 64.2 (8.9)          | 66.8 (8.0)             | 68.5 (8.7)          | < .001  |
| Male                                  | 177.0 (38.0%)  | 385.0 (48.1%)       | 203.0 (51.8%)          | 168.0 (62.2%)       | < .001  |
| Body high, cm                         | 158.0 (7.7)    | 158.7 (8.8)         | 158.7 (8.3)            | 160.0 (8.4)         | .029    |
| BMI, kg/m²                            | 26.8 (3.9)     | 27.2 (5.9)          | 26.5 (3.8)             | 26.2 (3.7)          | .008    |
| Waist circumference, cm               | 87.4 (9.9)     | 89.3 (9.2)          | 88.7 (9.2)             | 88.3 (8.4)          | .125    |
| Duration of DM, years                 | 5.1 (4.7)      | 6.4 (5.4)           | 8.5 (7.1)              | 9.2 (6.8)           | < .001  |
| Blood pressure                        |               |                     |                        |                    |         |
| SBP, mmHg                             | 133.7 (15.9%)  | 136.9 (16.6%)       | 137.5 (16.1%)          | 139.0 (15.8%)       | < .001  |
| DBP, mmHg                             | 80.4 (11.1%)   | 80.5 (10.7%)        | 80.1 (10.6%)           | 79.6 (11.1%)        | .671    |
| Blood sugar                           |               |                     |                        |                    |         |
| Blood sugar, mg/dL                    | 158.7 (52.6%)  | 160.7 (55.8%)       | 157.0 (52.0%)          | 163.9 (57.0%)       | .421    |
| PC Blood sugar, mg/dL                 | 208.5 (74.3%)  | 209.4 (81.0%)       | 211.9 (82.4)           | 232.9 (92.3%)       | .061    |
| HbA1c, %                              | 7.9 (1.6)      | 8.0 (1.6)           | 8.0 (1.6)              | 8.1 (1.6)           | .502    |
| BUN, mg/dL                            | 17.4 (10.0%)   | 17.3 (7.4)          | 20.4 (12.8)            | 20.5 (12.2)         | < .001  |
| Creatinine, mg/dL                     | 1.0 (0.9)      | 1.0 (0.6)           | 1.1 (0.7)              | 1.2 (0.8)           | .002    |
| Cholesterol, mg/dL                    | 203.5 (39.6%)  | 203.2 (43.1%)       | 202.2 (43.3)           | 199.0 (42.7%)       | .516    |
| LDL, mg/dL                            | 124.8 (31.6%)  | 126.5 (33.1%)       | 126.8 (34.9)           | 124.5 (37.2%)       | .804    |
| HDL, mg/dL                            | 45.3 (14.9%)   | 43.8 (13.4)         | 43.7 (13.2)            | 40.9 (10.5)         | .004    |
| Triglyceride, mg/dL                   | 160.0 (112.6%) | 172.1 (129.5%)      | 163.5 (116.8)          | 175.6 (106.3)       | .255    |
| Medication use                        |               |                     |                        |                    |         |
| Aspirin                               | 146 (31%)      | 283 (35%)           | 156 (39%)              | 121 (44%)           | .001    |
| ACEI                                  | 58 (12%)       | 122 (15%)           | 63 (16%)               | 41 (15%)            | .438    |
| ARB                                   | 80 (17%)       | 170 (21%)           | 72 (18%)               | 59 (21%)            | .229    |
| Statin                                | 124 (26%)      | 208 (26%)           | 120 (30%)              | 66 (24%)            | .269    |
| OHA                                   | 395 (84.8%)    | 699 (87.4%)         | 322 (82.1%)            | 223 (82.6%)         | .204    |
| Insulin                               | 10 (2.1%)      | 12 (1.5%)           | 10 (2.6%)              | 14 (5.2%)           | .009    |
| OHA + Insulin                         | 11 (2.4%)      | 33 (4.1%)           | 23 (5.9%)              | 18 (6.7%)           | .020    |
| Risk factor group                     |               |                     |                        |                    |         |
| RF=0                                  | 21.0 (4.5%)    | 25.0 (3.1%)         | 9.0 (2.3%)             | 7.0 (2.6%)          | < .001  |
| RF=1                                  | 113.0 (24.2%)  | 127.0 (15.9%)       | 48.0 (12.2%)           | 44.0 (16.3%)        |         |
| RF=2                                  | 171.0 (36.7%)  | 336.0 (42.0%)       | 151.0 (38.5%)          | 90.0 (33.3%)        |         |
| RF > =3                               | 161.0 (34.5%)  | 312.0 (39.0%)       | 184.0 (46.9%)          | 129.0 (47.8%)       |         |
| Risk factor                           |               |                     |                        |                    |         |
| Smoking                               | 129.0 (27.7%)  | 234.0 (29.3%)       | 123.0 (31.4%)          | 108.0 (40.0%)       | .003    |
| Family history of CAD                 | 42.0 (9.0%)    | 51.0 (6.4%)         | 26.0 (6.6%)            | 21.0 (7.8%)         | < .001  |
| Hypercholesterolemia                  | 351.0 (75.3%)  | 608.0 (76.0%)       | 312.0 (79.6%)          | 192.0 (71.1%)       | < .001  |
| Macro/microalbuminuria                | 172.0 (36.9%)  | 322.0 (40.3%)       | 185.0 (47.2%)          | 124.0 (45.9%)       | .008    |
| Hypertension                          | 277.0 (59.4%)  | 587.0 (73.4%)       | 294.0 (75.0%)          | 210.0 (77.8%)       | < .001  |

AU, Agatston unit; CAC, coronary artery calcium; BMI, body mass index; DM, diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; BUN, blood urea nitrogen; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; OHA, oral hypoglycemic agent; RF, risk factor; CAD, cardiovascular disease. Risk factors group were counted by smoking, family history of CAD, hypercholesterolemia, macro/microalbuminuria and hypertension.
CAC score = 0, but up to 28.6 and 38.3 per 1,000 person-year in patients with CAC > 400 (p < 0.001). Kaplan–Meier analysis of event-free survival curve for all clinical endpoints showed a significant difference among the 4 CAC score categories during the 8 years follow-up, with a lower event-free survival rate in patients with a higher CAC score (Fig. 2A, B, C, D). In four patients’ stratum with various risk factor burdens, the incidence rate of all-cause mortality and major CHD events increase with the CAC score (Fig. 3A, B). Individuals with no risk factor and CAC > 400 had much higher mortality and major CHD events compared with individuals with three or more risk factors but no CAC (40.0 and 12.2 per 1,000 person-year versus 6.0 and 6.1 per 1,000 person-year, respectively). In the Cox proportional regression analysis adjusted for age, T2DM duration, and number of risk factors, increasing CAC score was associated with higher hazard ratio (HR) of major CHD event and cardiac mortality, with 10.5- and 8.7-fold risk for CAC score > 400 versus CAC = 0 or 4.2- and 3.4-fold risk for CAC score 100–400 versus CAC = 0 (Table 3). Macro/microalbuminuria is a significant predictor of the clinical endpoints all-cause mortality (HR = 1.54, p = 0.003), cardiac mortality (HR = 2.67, p = 0.002), major CHD (HR = 1.45, p = 0.013), and ischemic stroke (HR = 1.77, p = 0.004). The incidence of ischemic stroke tended to increase as the severity of CAC increased; however, the association became non-significant after correction for confounding factors (Tables 2 and 3).

Discussion

This is the largest prospective study evaluating the relationship between long-term cardiovascular

![Fig. 1. Distribution of coronary artery calcium (CAC) scores by number of coronary risk factors](image)

Table 2. Incidence of Events According to Four Coronary Artery Calcium (CAC) Categories

| Variable                     | CAC=0 (N=466)  | 0<CAC≤100 (N=800) | 100<CAC≤400 (N=392) | CAC>400 (N=270) | P value |
|------------------------------|----------------|-------------------|---------------------|-----------------|---------|
|                              | N | % incidence per 1,000 Person-years | N | % incidence per 1,000 Person-years | N | % incidence per 1,000 Person-years | N | % incidence per 1,000 Person-years |
| All cause mortality^a        | 26 | 5.6% | 6.4 | 74 | 9.3% | 10.8 | 51 | 13.0% | 15.6 | 60 | 22.2% | 28.6 | < .001 |
| Cardiac mortality            | 3 | 0.6% | 0.8 | 12 | 1.5% | 1.8 | 9 | 2.3% | 2.7 | 19 | 7.0% | 8.6 | < .001 |
| Non-cardiac mortality        | 23 | 4.9% | 6.0 | 62 | 7.8% | 9.5 | 42 | 10.7% | 13.4 | 41 | 15.2% | 19.7 | < .001 |
| Major CHD^b                  | 16 | 3.4% | 3.9 | 67 | 8.4% | 9.8 | 49 | 12.5% | 15.3 | 75 | 27.8% | 38.3 | < .001 |
| AMI                          | 3 | 0.6% | 0.8 | 16 | 2.0% | 2.4 | 11 | 2.8% | 3.4 | 9 | 3.3% | 4.0 | .045 |
| Coronary revascularization   | 13 | 2.8% | 3.2 | 56 | 7.0% | 8.1 | 43 | 11.0% | 13.2 | 62 | 23.0% | 30.5 | < .001 |
| Ischemic stroke              | 16 | 3.4% | 4.1 | 43 | 5.4% | 6.5 | 23 | 5.9% | 7.1 | 29 | 10.7% | 13.5 | < .001 |

^aClinical endpoints include all-cause mortality, cardiac mortality, acute myocardial infarction (AMI), any coronary revascularization [percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG)] and ischemic stroke.

^bMajor coronary heart disease (CHD) events were defined as combinations of cardiac mortality, AMI and any coronary revascularization.
Fig. 2.
Kaplan–Meier Cumulative-Event Curves for all-cause mortality (A), cardiac mortality (B), coronary revascularization (C), and major coronary heart disease (D) in participants with diabetes by four coronary artery calcium (CAC) categories. The differences between the four CAC categories among all survival curves are statistically significant (all $p < 0.05$).

Table 3. The Associations between CAC Categories and Clinical Endpoints in Participants with Diabetes Examining by Cox Proportional Hazards Regression model

| CAC score category | All cause mortality Hazard Ratio (95% CI) p value | Cardiac mortality Hazard Ratio (95% CI) p value | Non-cardiac mortality Hazard Ratio (95% CI) p value |
|--------------------|---------------------------------|---------------------------------|---------------------------------|
| CAC=0              | 1 (reference)                  | 1 (reference)                  | 1 (reference)                  |
| 0<CAC≤100          | 1.07 (0.63-1.81) .797          | 2.16 (0.46-10.11) .329         | 0.95 (0.54-1.67) .862          |
| 100<CAC≤400        | 1.45 (0.84-2.52) .184          | 3.35 (0.69-16.30) .134         | 1.22 (0.68-2.22) .505          |
| CAC>400            | 2.08 (1.18-3.66) .011          | 8.67 (1.87-40.27) .006         | 1.38 (0.73-2.59) .324          |
|                    | Cox model: $p < .001$          | Cox model: $p < .001$          | Cox model: $p < .001$          |

| CAC score category | Major CHD Hazard Ratio (95% CI) p value | Coronary revascularization Hazard Ratio (95% CI) p value | AMI Hazard Ratio (95% CI) p value | Ischemic stroke Hazard Ratio (95% CI) p value |
|--------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| CAC=0              | 1 (reference)                  | 1 (reference)                  | 1 (reference)                  | 1 (reference)                  |
| 0<CAC≤100          | 3.14 (1.54-6.41) .002          | 3.39 (1.52-7.58) .003          | 5.71 (0.73-44.44) .096         | 1.19 (0.63-2.25) .590          |
| 100<CAC≤400        | 4.18 (1.99-8.80) <.001         | 4.57 (1.98-10.52) <.001        | 6.31 (0.76-52.23) .087         | 1.18 (0.57-2.43) .652          |
| CAC>400            | 10.52 (5.07-21.83) <.001       | 10.83 (4.76-24.62) <.001       | 4.19 (0.44-39.51) .211         | 2.11 (2.11-4.32) .410          |
|                    | Cox model: $p < .001$          | Cox model: $p < .001$          | Cox model: $p < .047$          | Cox model: $p < .001$          |

All models were adjusted for age, diabetes duration and the number of risk factors.
been shown to be closely related with total coronary artery atherosclerotic plaque burden, and CAC scanning provided a direct means of measuring atherosclerosis\textsuperscript{25}). Incidence of CAC is strongly associated with traditional atherosclerotic risk factors such as age, sex, race, body mass index, waist-hip ratio, diabetes, history of hypertension, and family history of CHD\textsuperscript{26-28}). But the distribution of CAC is heterogeneous across age and risk factor burden in the general population\textsuperscript{18, 19, 29}). High atherosclerotic burden is not an obligatory finding in older patients or those with multiple risk factors. Likewise, young patients and those with no or one risk factor may have increased burden of atherosclerosis. Results from the Multi-Ethnic Study of Atherosclerosis (MESA) revealed a direct relationship between Framingham outcome and severity of CAC in asymptomatic T2DM patients. Of the included patients, 23.5% had a CAC score of zero and severe CAC (CAC score $>$ 400) was present in 14.7%. Those patients of older age, male sex, longer diabetic history, and multiple traditional risk factors tended to have a higher CAC score. Increasing severity of CAC significantly predicted higher long-term all-cause mortality and major CHD events irrespective of risk factor burden. Diabetic patients without CAC had very low event rate.

Subclinical Atherosclerosis and Risk Factor Burden

Measuring atherosclerotic plaque burden must take into account the aggregated effect of all known and unknown risk factors. The extent of CAC has been shown to be closely related with total coronary artery atherosclerotic plaque burden, and CAC scanning provided a direct means of measuring atherosclerosis\textsuperscript{25}). Incidence of CAC is strongly associated with traditional atherosclerotic risk factors such as age, sex, race, body mass index, waist-hip ratio, diabetes, history of hypertension, and family history of CHD\textsuperscript{26-28}). But the distribution of CAC is heterogeneous across age and risk factor burden in the general population\textsuperscript{18, 19, 29}). High atherosclerotic burden is not an obligatory finding in older patients or those with multiple risk factors. Likewise, young patients and those with no or one risk factor may have increased burden of atherosclerosis. Results from the Multi-Ethnic Study of Atherosclerosis (MESA) revealed a direct relationship between Framingham

![Incidence rates of all-cause mortality (A) and major coronary heart disease (B) among subgroups of risk factor burden and CAC category.](image_url)
risk score (FRS) and the prevalence and amount of CAC, but the distribution of CAC within FRS groups remains heterogeneous\(^{30}\). This heterogeneity between traditional risk factors and atherosclerosis burden was also observed in our diabetic patients. Our study showed there was no difference in the distribution of CAC severity in diabetic patients with two or fewer risk factors. Only clustering of three or more risk factors predict more severe CAC, but still one-fifth of the patients with high risk-factor burden had no CAC.

**CAC and CHD Events in the General Population**

In several prospective or retrospective, population-based, or patient-referred studies, CAC score has consistently been shown to predict cardiac events in the asymptomatic general population with significant incremental value over conventional risk factor-based assessment\(^{14-17,31-33}\). In a large cohort of 25,253 asymptomatic subjects, Budoff \textit{et al.} showed that an increasing CAC score was associated with increased risk of all-cause mortality after a mean follow-up of 6.8 years\(^{39}\). From the MESA analysis, the HRs for a coronary event was 7.73 for those with a CAC score of 101 to 300, and 9.67 for a CAC score >300 as compared with patients with a CAC score of 0\(^{15}\). CAC score was superior to FRS in the prediction of total CHD events after a mean follow-up of 4.3 years with the area under the curve for CAC score being 0.79 as compared to 0.68 for FRS \((p<0.001)\)^{30}. A CAC score >400 is considered as a CHD risk equivalent, with the 10-year event rate exceeding 20% in asymptomatic patients. The annual event rate in patients with a CAC score of zero is very low (0.11% to 0.17%), making a CAC score of zero a strong negative predictor of CHD events\(^{34}\). The 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease has suggested class IIa recommendation for CAC score measurement to guide clinician–patient risk discussion in borderline-to-intermediate-risk groups and certain subgroups, such as women and young adults\(^{35}\).

**CAC and Cardiovascular Risk in T2DM Patients**

For the asymptomatic T2DM population, there were a few studies demonstrating increased prevalence and severity of CAC, wide variability of cardiovascular risk in different CAC categories, and worse prognosis associated with increasing CAC severity\(^{21-24,36,37}\). In a 8.5-year follow-up of 1,343 T2DM patients from the MESA and Heinz–Nixdorf–Recall studies, Yeboah \textit{et al.} showed that CAC score was a better predictor of incident cardiovascular events compared with FRS and the United Kingdom Prospective Diabetes Study score (area under the curve, 0.76, 0.70, and 0.69, respectively; all \(p<0.05\))\(^{29}\). Our study showed similar findings; progressively higher incidence of all-cause mortality and major coronary heart events were observed with increasing severity of CAC under various risk factor burden in this largest T2DM cohort over the mean 8.4 years (Fig. 2, 3A, 3B). After confounding factors adjustment, patients with a CAC score >400 had a significant higher HR for all-cause mortality (2.08), cardiac mortality (8.67), and major CHD (10.5) as compared with patients with a zero CAC score (Table 3). Patients without CAC account for 13.4% to 39.3% of the study population in various studies\(^{23, 24, 28, 30}\), being 24.2% in our report. They had the lowest incidence rate of all-cause mortality and major CHD events (6.4 and 3.9 per 1000 person-year, respectively) under various risk factor burden (Table 2, Fig. 3A, 3B). Even patients with three or more risk factors but zero CAC had a lower major CHD event rate than patients with CAC >400 and no or one risk factor (6.1 versus 12.2 or 32.9 per 1000 person-year). Our study and prior reports provide strong evidence that diabetes per se is not a CHD risk equivalent and CAC determination is a better strategy for risk stratification in mid-to-long-term cardiovascular outcome.

**CAC and Aspirin for Primary Prevention in T2DM**

The benefits and harms of aspirin for primary prevention of cardiovascular disease in the diabetic population have been widely studied in the past decades but remain controversial\(^{38, 39}\). Recommendations from various guidelines for aspirin use have also been inconsistent. A recent meta-analysis including 12 randomized controlled trials based on 34,227 diabetic participants with a median treatment duration of 5 years showed that there was a significant reduction in risk of major adverse cardiovascular events with a HR of 0.89 (0.83–0.95), comparing aspirin use with no aspirin intake. Aspirin use had no effect on all-cause mortality and other endpoints, and had also no influence on major bleeding\(^{40}\). Another meta-analysis including 10 studies and 30,448 participants showed that aspirin use was associated with a decrease in primary composite cardiovascular outcome with a HR of 0.89 (0.80–1.00), but no effect on secondary cardiovascular outcomes. Significant increase in major bleeding (HR, 1.29) and major gastrointestinal bleeding (HR, 1.35) were described as being associated with aspirin use\(^{41}\). Therefore, the use of low-dose aspirin for primary prevention in diabetes should be individualized according to personal baseline cardiovascular and bleeding risk as per recommendation from latest American Diabetes Association (ADA) standards of medical care in
diabetes. An analysis of aspirin use for primary prevention of CHD from the MESA study showed nondiabetic individuals with a CAC score \( \geq 100 \) had an estimated net benefit regardless of their traditional risk status while individuals with zero CAC were estimated to receive net harm from aspirin use\(^{42}\). In an observation of 2,384 diabetic patients after a follow-up of 5.6 \( \pm \) 2.6 years, Silverman \textit{et al.} reported that CAC can help risk stratification and a CAC score \( \geq 100 \) may aid in the selection of patients who may benefit from aspirin therapy within the low and intermediate-risk groups based on age and risk factors profile\(^{43}\). Among our study population, aspirin use could be suggested in 96.5% of the participants according to ADA’s risk factors criteria, but may be beneficial only in 34.3% as per CAC score >100 criteria. Accordingly, CAC scoring may help decision-making for aspirin use in primary prevention.

**Limitations**

The major limitation of our study was that all cardiovascular endpoints were ascertained by a study nurse via telephone interview with the patient or family retrospectively after a mean 8.4 years’ interval. Only 31.3% of the patients’ outcomes were confirmed by formal hospital chart records, but were not adjudicated by an independent committee. There were probably missing nonfatal cardiovascular events in some patients, but the accuracy of all-cause mortality and cardiac mortality may be less affected by the method of data acquisition.

**Conclusions**

Among the asymptomatic T2DM population, there is significant heterogeneity between traditional coronary risk factors and atherosclerotic burden, represented by the CAC score. Only multiple risk factors predict increasing severity of CAC. Increasing severity of CAC was associated with higher all-cause mortality, cardiac mortality, and incident cardiovascular events. A CAC score \( > 400 \) or zero can identify high- or low-risk subsets irrespective of risk factor burden. Measurement of CAC provides better prognostication of adverse cardiovascular events than traditional risk factors in asymptomatic T2DM patients. Additional research is needed to confirm the utility of CAC screening to guide selection of diabetic patients for aspirin therapy in the primary prevention of cardiovascular disease.

**Acknowledgements**

We would like to thank the Public Health Bureau Yilan County in assisting patients recruitment from the Lan-Yan Diabetes Shared Care Network. We also thank the study nurse Ms. LF Zhuang in conducting telephone interview for clinical endpoints ascertainment. Parts of study result were presented as poster at the Annual Congress of European Society of Cardiology 2008 and oral presentation at the 12\textsuperscript{th} Congress of the Asian-Pacific Society of Atherosclerosis and Vascular Disease September 20-22, 2019.

**Author Contribution**

MHL, SLC, CCC, WCC, and YCH contributed to the conception and design of the work. MHL, YLW, SLC, WCC, and YCH contributed to the acquisition, analysis and interpretation of data for the work. MHL and YLW drafted the manuscript. All authors critically revised the manuscript, gave final approval and agree to be accountable for all aspects of work ensuring accuracy and integrity.

**Disclosure of Potential Conflicts of Interest**

All authors declare that they have no conflict of interest.

**Funding**

This study received financial support from Lo-Hsu Medical Foundation.

**Ethical Approval**

The institutional review board at Lo-Tung Poh-Ai Hospital approved the study with review board number (OMCP-97-013).

**References**

1) Gu K, Cowie CC and Harris MI: Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care, 1998; 21: 1138-1145
2) Kannel W and McGee D: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care, 1979; 2: 120-126
3) Sarwar N, Gao P, Seshasai SR, Robin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stamper M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK and Danesh J: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis
15) Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M and Bluemke DA: Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med, 2008; 358: 1336-1345

16) Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD and Greenland P: Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA, 2010; 303: 1610-1616

17) Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, Goff DC, Greenland P and Harrington DM: Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA, 2012; 308: 788-795

18) Nasir K, Rubin J, Blaha MJ, Shaw LJ, Blankstein R, Rivera JJ, Khan AN, Berman D, Raggi P and Callister T: Interplay of Coronary Artery Calcification and Traditional Risk Factors for the Prediction of All-Cause Mortality in Asymptomatic Individuals. Circ Cardiovasc Imaging, 2012; 5: 467-473

19) Blaha MJ, Silverman MG and Budoff MJ: Is there a role for coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease?: Clinical risk scores are not sufficient to define primary prevention treatment strategies among asymptomatic patients. Circ Cardiovasc Imaging, 2014; 7: 398-408

20) Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, Lipkin D and Lahiri A: Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J, 2006; 27: 713-721

21) Wong ND, Rozanski A, Gransar H, Miranda-Peats R, Kang X, Hayes S, Shaw L, Friedman J, Polk D and Berman DS: Metabolic syndrome and diabetes are associated with an increased likelihood of inducible myocardial ischemia among patients with subclinical atherosclerosis. Diabetes Care, 2005; 28: 1445-1450

22) Malik S, Zhao Y, Budoff M and et al. : Coronary artery calcium score for long-term risk classification in individu- als with type 2 diabetes and metabolic syndrome from the multi-ethnic study of atherosclerosis. JACC Cardioiology, 2017; 2: 1332-1340

23) Yeboah J, Erbel R, Delaney JC, Nance R, Guo M, Bertoni AG, Budoff M, Moebus S, Jäckel K-H and Burke GL: Development of a new diabetes risk prediction tool for incident coronary heart disease events: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. Atherosclerosis, 2014; 236: 411-417

24) Raggi P, Shaw LJ, Berman DS and Callister TQ: Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol, 2004; 43: 1663-1669

25) Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF and Schwartz RS: Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation, 1995; 92: 2157-2162

26) Elkess RS, Feher MD, Flather MD, Godsland IF, Nugara F, Richmond W, Rubens MB, Wang D and PREDICT Study Group: The association of coronary calcium score and conventional cardiovascular risk factors in Type 2 diabetic subjects asymptomatic for coronary heart disease (The PREDICT Study). Diabet Med, 2004; 21: 1129-1134
27) Nasir K, Budoff MJ, Wong ND, Scheuner M, Herrington D, Arnett DK, Szklo M, Greenland P and Blumenthal RS: Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation, 2007; 116: 619-626

28) Lehmann N, Möhlenkamp S, Mahabadi AA, Schmermund A, Roggenbuck U, Seibel R, Grönenmeyer D, Budde T, Dragano N and Stang A: Effect of smoking and other traditional risk factors on the onset of coronary artery calcification: results of the Heinz Nixdorf recall study. Atherosclerosis, 2014; 232: 339-345

29) Tota-Maharaj R, Blaha MJ, McEvoy JW, Blumenthal RS, Muse ED, Budoff MJ, Shaw LJ, Berman DS, Rana JS and Rumberger J: Coronary artery calcium for the prediction of mortality in young adults <45 years old and elderly adults> 75 years old. Eur Heart J, 2012; 33: 2955-2962

30) Okwuosa TM, Greenland P, Ning H, Liu K, Bild DE, Burke GL, Eng J and Lloyd-Jones DM: Distribution of coronary artery calcium scores by Framingham 10-year risk strata in the MESA (Multi-Ethnic Study of Atherosclerosis): potential implications for coronary risk assessment. J Am Coll Cardiol, 2011; 57: 1838-1845

31) Greenland P, LaBree L, Azen SP, Doherty TM and Detryano RC: Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA, 2004; 291: 210-215

32) Arad Y, Goodman KJ, Roth M, Newstein D and Guerci AD: Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol, 2005; 46: 158-165

33) Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Tseng PH, Flores FR, Callister TQ, Raggi P, Berman DS and Mosler TP: Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol, 2007; 49: 1860-1870

34) Hecht HS: Coronary artery calcium scanning: past, present, and future. JACC Cardiovascular Imaging, 2015; 8: 579-596

35) Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khara A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS, Williams KA, Yeoob K and Ziaeian B: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, 2019; 74: 1376-1414

36) Becker A, Leber AW, Becker C, von Ziegler F, Tittus J, Schroeder I, Steinbeck G and Knez A: Predictive value of coronary calcifications for future cardiac events in asymptomatic patients with diabetes mellitus: a prospective study in 716 patients over 8 years. BMC Cardiovasc Disord, 2008; 8: 27

37) Elkeles RS, Godsland IF, Feher MD, Rubens MB, Roughton M, Nugara F, Humphries SE, Richmond W and Flather MD: Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J, 2008; 29: 2244-2251

38) De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G and Nicolucci A: Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. Br Med J, 2009; 339: b4531

39) Kunutsor SK, Seidu S and Khunti K: Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Br Med J, 2009; 339: b4531

40) Seidu S, Kunutsor SK, Sesso HD, Gaziano JM, Buring JE, Roncaglioni MC and Khunti K: Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol, 2019; 18: 70

41) Zheng SL and Roddick AJ: Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA, 2019; 321: 277-287

42) Miedema MD, Duprez DA, Misialek JR, Blaha MJ, Nasir K, Silverman MG, Blankstein R, Budoff MJ, Greenland P and Folsom AR: Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes, 2014; 7: 453-460

43) Silverman MG, Blaha MJ, Budoff MJ, Rivera JJ, Raggi P, Shaw LJ, Berman D, Callister T, Rumberger JA and Rana JS: Potential implications of coronary artery calcium testing for guiding aspirin use among asymptomatic individuals with diabetes. Diabetes Care, 2012; 35: 624-626